These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 3870620)

  • 1. Simplified evaluation and documentation of data from glucose controlled insulin infusion systems--artefact handling.
    Peters A; Müller-Esch G; Scriba PC
    Life Support Syst; 1985; 3 Suppl 1():588-92. PubMed ID: 3870620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a glucose-controlled insulin infusion system in children and adolescents with insulin-dependent diabetes.
    Golden MP; Myers GL; Tanner SM; Marrero DG; Charles MA
    Pediatrics; 1982 Jul; 70(1):36-42. PubMed ID: 7088631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feedback control dynamics for glucose controlled insulin infusion system.
    Clemens AH
    Med Prog Technol; 1979 Jun; 6(3):91-8. PubMed ID: 481365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and hormonal responses during a glucose controlled insulin infusion (Biostator) in subjects with impaired glucose tolerance.
    Ratzmann KP; Schneider U; Peters U; Ziegler M; Schulz B
    Exp Clin Endocrinol; 1984 May; 83(3):334-42. PubMed ID: 6381073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous insulin infusion in the treatment of juvenile-onset diabetes.
    Buysschaert M; Lejeune M; Lambert AE
    Diabete Metab; 1981 Sep; 7(3):189-93. PubMed ID: 7319116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal H infinity insulin injection control for blood glucose regulation in diabetic patients.
    Chee F; Savkin AV; Fernando TL; Nahavandi S
    IEEE Trans Biomed Eng; 2005 Oct; 52(10):1625-31. PubMed ID: 16235648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified evaluation and documentation of data from glucose-controlled insulin infusion systems. Part II: Artefact handling.
    Peters A; Müller-Esch G; Scriba PC
    Biomed Tech (Berl); 1986; 31(1-2):2-5. PubMed ID: 3754160
    [No Abstract]   [Full Text] [Related]  

  • 8. The dawn phenomenon--fact or artefact?
    Gale EA
    Neth J Med; 1985; 28 Suppl 1():50-2. PubMed ID: 3892340
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes.
    Charles MA; Szekeres A; Staten M; Worcester B; Walsh KM
    Diabetes Care; 1983; 6 Suppl 1():29-34. PubMed ID: 6343034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of an artificial B-cell in clinic and experimental medicine].
    Fischer U; Bruns W; Jutzi E; Ratzmann KP; Abel P; Bombor H; Salzsieder E; Freyse EJ
    Z Gesamte Inn Med; 1981 Jan; 36(1):19-26. PubMed ID: 7013292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Feasibility and reproductibility of a euglycemic hyperinsulinic glucose clamp technic].
    Gin H; Brunel PG; Brottier E; Aubertin J; Drouin P; Debry G
    Diabete Metab; 1984 Jan; 10(1):36-8. PubMed ID: 6373424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose monitoring and pump data management software operated on a personal digital assistant can contribute to improve diabetes control in CSII-treated patients.
    Boizel R; Benhamou PY; Renard E;
    Diabetes Metab; 2007 Sep; 33(4):314-5. PubMed ID: 17475533
    [No Abstract]   [Full Text] [Related]  

  • 13. Derivative weighted active insulin control modelling and clinical trials for ICU patients.
    Doran CV; Hudson NH; Moorhead KT; Chase JG; Shaw GM; Hann CE
    Med Eng Phys; 2004 Dec; 26(10):855-66. PubMed ID: 15567701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetes.
    Capaldo B; Home PD; Massi-Benedetti M; Worth R; Cook DB; Heaton A; Alberti KG
    Diabetes Res; 1984 Nov; 1(4):187-93. PubMed ID: 6397293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of the endocrine artificial pancreas (GCIIS; Biostator) in heart surgery].
    Calabrese G; Bueti A; Zega G; Bellomo G; Antonella MA; Giombolini A; Tardioli F; Massi-Benedetti M; Palminiello A
    Minerva Med; 1982 Dec; 73(49-50):3509-14. PubMed ID: 7155400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas.
    Matsuo Y; Shimoda S; Sakakida M; Nishida K; Sekigami T; Ichimori S; Ichinose K; Shichiri M; Araki E
    J Artif Organs; 2003; 6(1):55-63. PubMed ID: 14598126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A robust controller for insulin pumps based on H-infinity theory.
    Kienitz KH; Yoneyama T
    IEEE Trans Biomed Eng; 1993 Nov; 40(11):1133-7. PubMed ID: 8307597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not the artificial beta cell algorithms but their parameter values are important in automated glucose control of insulin-dependent diabetes.
    Fischer U; Jutzi E; Albrecht G; Abel P; Salzsieder E; Freyse EJ; Detscheff W; Lemke K
    Trans Am Soc Artif Intern Organs; 1983; 29():488-91. PubMed ID: 6673274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tight glycaemic control: a prospective observational study of a computerised decision-supported intensive insulin therapy protocol.
    Shulman R; Finney SJ; O'Sullivan C; Glynne PA; Greene R
    Crit Care; 2007; 11(4):R75. PubMed ID: 17623086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled drug delivery in the treatment of diabetes mellitus.
    Irsigler K; Kritz H; Lovett RG
    Crit Rev Ther Drug Carrier Syst; 1985; 1(3):189-280. PubMed ID: 3912064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.